← SynDRA
AMPRENAVIR
SynDRA canonical compound SYN0000961 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · OTC |
|---|
| Mechanism of action | HIV protease inhibitor |
|---|
| Indication | human immunodeficiency virus (HIV-1) |
|---|
| Disease area | infectious disease |
|---|
All known targets
- CTSD
- CYP3A4
- HIV PR
- HIV-1 protease
- TBXAS1
- gag-pol
- pol
- protease
Mechanisms of action (all sources)
- protease inhibitor
- HIV PR INHIBITOR
- pol INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- MLNR
- CYP3A5
- ABCB1
- KCNH2
- MMP1
- MC5R
- MC4R
- MC3R
- MAPK3
- MAPK14
- MAPK1
- MAOA
- LMNA
- LCK
- HTR6
- NPY1R
- HTR3A
- HTR2C
- HTR2B
- HTR2A
- HTR1A
- HRH3
- HRH2
- HRH1
- HMGCR
- HDAC6
- GHSR
- MMP9
- NPY2R
- FLT1
- NR1I2
- TBXA2R
- TACR2
- TACR1
- SLCO2B1
- SLCO1B3
- SLCO1B1
- SLC6A4
- SLC6A3
- SLC6A2
Drug classes
- HIV Protease Inhibitors
- Anti-Bacterial Agents
- Anti-HIV Agents
- Anti-Infective Agents
- Anti-Retroviral Agents
- Antibiotics, Antitubercular
- Antitubercular Agents
- Antiviral Agents
- Enzyme Inhibitors
- Protease Inhibitors
- Viral Protease Inhibitors
- Protease Inhibitor
ATC classes
- J05A · DIRECT ACTING ANTIVIRALS
Cross-references
Synonyms
- AGENERASE
- agenerase
- angenerase
- samprenavir
- 141 W94
- 141W94
- J05AE05
- KVX-478
- VX-478
- Agenerase
- AMV
- Amprenavir[usan]
- Prozei
- Vertex
- Amprenavir [USAN]
- VX478
- Vertex VX478
- Agenerase (TM)
- Agenerase (TN)
- DRG-0258
- GNA & Amprenavir
- HHA & Amprenavir
- Amprenavir (JAN/USAN/INN)
- 5S0W860XNR
- KVX 478
- VX 478
- CHEBI:40050
- Amprenavirum
- RefChem:54192
- DTXCID601765661
- C25H35N3O6S
- MFCD00934214
- Amprenavir (agenerase)
- HSDB 7157
- UNII-5S0W860XNR
- Amprenavir [USAN:INN:BAN]
- 1hpv
- 3ekp
Reported adverse events
- Fatigue
- Nausea
- Vomiting
- Myocardial infarction
- Nephrolithiasis
Look up AMPRENAVIR in the interactive SynDRA portal →